The I1-imidazoline receptor in PC12 pheochromocytoma cells activates protein kinases C, extracellular signal-regulated kinase (ERK) and c-jun N-terminal kinase (JNK)

被引:47
作者
Edwards, L
Fishman, D
Horowitz, P
Bourbon, N
Kester, M
Ernsberger, P [1 ]
机构
[1] Case Western Reserve Univ, Sch Med, Dept Nutr, Cleveland, OH 44106 USA
[2] Case Western Reserve Univ, Sch Med, Dept Pharmacol, Dept Neurosci, Cleveland, OH 44106 USA
[3] Penn State Univ, Milton S Hershey Med Ctr, Dept Pharmacol, Hershey, PA 17033 USA
关键词
arachidonic acid metabolism; imidazoline; PC12; cells; pheochromocytoma; phospholipases C; receptors;
D O I
10.1046/j.1471-4159.2001.00632.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We sought to further elucidate signal transduction pathways for the I-1-imidazoline receptor in PC12 cells by testing involvement of protein kinase C (PKC) isoforms (beta (II), epsilon, xi), and the mitogen-activated protein kinases (MAPK) ERK and JNK. Stimulation of I-1-imidazoline receptor with moxonidine increased enzymatic activity of the classical beta (II) isoform in membranes by about 75% and redistributed the atypical isoform into membranes (40% increase in membrane-bound activity), but the novel isoform of PKC was unaffected. Moxonidine and clonidine also increased by greater than two-fold the proportion of ERK-1 and ERK-2 in the phosphorylated active form. In addition, JNK enzymatic activity was increased by exposure to moxonidine. Activation of ERK and JNK followed similar time courses with peaks at 90 min. The action of moxonidine on ERK activation was blocked by the I-1-receptor antagonist efaroxan and by D609, an inhibitor of phosphatidylcholine-selective phospholipase C (PC-PLC), previously implicated as the initial event in I-1-receptor signaling. Inhibition or depletion of PKC blocked activation of ERK by moxonidine. Two-day treatment of PC12 cells with the I-1/alpha (2)-agonist clonidine increased cell number by up to 50% in a dose related manner. These data suggest that ERK and JNK, along with PKC, are signaling components of the I-1-receptor pathway, and that this receptor may play a role in cell growth.
引用
收藏
页码:931 / 940
页数:10
相关论文
共 36 条
[1]   No role for Ca++ or protein kinase C in alpha-1A adrenergic receptor activation of mitogen-activated protein kinase pathways in transfected PC12 cells [J].
Berts, A ;
Zhong, HY ;
Minneman, KP .
MOLECULAR PHARMACOLOGY, 1999, 55 (02) :296-303
[2]   Changes of nuclear protein kinase C activity and isotype composition in PC12 cell proliferation and differentiation [J].
Borgatti, P ;
Mazzoni, M ;
Carini, C ;
Neri, LM ;
Marchisio, M ;
Bertolaso, L ;
Previati, M ;
Zauli, G ;
Capitani, S .
EXPERIMENTAL CELL RESEARCH, 1996, 224 (01) :72-78
[3]  
BOUSQUET P, 1984, J PHARMACOL EXP THER, V230, P232
[4]   POTENTIAL ROLE OF IMIDAZOLINE (I-1) RECEPTORS IN MODULATING AQUEOUS-HUMOR DYNAMICS [J].
CAMPBELL, WR ;
POTTER, DE .
JOURNAL OF OCULAR PHARMACOLOGY, 1994, 10 (01) :393-402
[5]  
Cobb RR, 1996, MOL PHARMACOL, V49, P998
[6]   NERVE GROWTH FACTOR-INDUCED DIFFERENTIATION OF PC12 CELLS EMPLOYS THE PMA-INSENSITIVE PROTEIN-KINASE C-ZETA ISOFORM [J].
COLEMAN, ES ;
WOOTEN, MW .
JOURNAL OF MOLECULAR NEUROSCIENCE, 1994, 5 (01) :39-57
[7]   Sphingolipid metabolites differentially regulate extracellular signal-regulated kinase and stress-activated protein kinase cascades [J].
Coroneos, E ;
Wang, YZ ;
Panuska, JR ;
Templeton, DJ ;
Kester, M .
BIOCHEMICAL JOURNAL, 1996, 316 :13-17
[8]   USE OF AN AQUEOUS SOLUBLE TETRAZOLIUM FORMAZAN ASSAY FOR CELL-GROWTH ASSAYS IN CULTURE [J].
CORY, AH ;
OWEN, TC ;
BARLTROP, JA ;
CORY, JG .
CANCER COMMUNICATIONS, 1991, 3 (07) :207-212
[9]   ACTIVATION OF MAP KINASE KINASE IS NECESSARY AND SUFFICIENT FOR PC12 DIFFERENTIATION AND FOR TRANSFORMATION OF NIH 3T3 CELLS [J].
COWLEY, S ;
PATERSON, H ;
KEMP, P ;
MARSHALL, CJ .
CELL, 1994, 77 (06) :841-852
[10]   'Seeing through a glass darkly': casting light on imidazoline 'I' sites [J].
Eglen, RM ;
Hudson, AL ;
Kendall, DA ;
Nutt, DJ ;
Morgan, NG ;
Wilson, VG ;
Dillon, MP .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1998, 19 (09) :381-390